Marion Wittmann
Overview
Explore the profile of Marion Wittmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scott L, Puryear C, Belfort G, Raines S, Hughes Z, Matthews L, et al.
Mov Disord
. 2022 Mar;
37(6):1193-1201.
PMID: 35257414
Background: Essential tremor is the most common movement disorder with clear unmet need. Mounting evidence indicates tremor is caused by increased neuronal burst firing and oscillations in cerebello-thalamo-cortical circuitry and...
2.
Kahlig K, Scott L, Hatch R, Griffin A, Martinez Botella G, Hughes Z, et al.
Epilepsia
. 2022 Jan;
63(3):697-708.
PMID: 35037706
Objective: This study investigates the effects of PRAX-562 on sodium current (I ), intrinsic neuronal excitability, and protection from evoked seizures to determine whether a preferential persistent I inhibitor would...
3.
Griffin A, Kahlig K, Hatch R, Hughes Z, Chapman M, Antonio B, et al.
ACS Med Chem Lett
. 2021 Apr;
12(4):593-602.
PMID: 33859800
The gene encodes the sodium-activated potassium channel K1.1 (Slack, Slo2.2). Variants in the gene induce a gain-of-function (GoF) phenotype in ionic currents and cause a spectrum of intractable neurological disorders...
4.
Farley B, Morozova E, Dion J, Wang B, Harvey B, Gianni D, et al.
Mol Cell Neurosci
. 2019 Jul;
99:103393.
PMID: 31356882
Enhancing remyelination is a key therapeutic strategy for demyelinating diseases such as multiple sclerosis. To achieve this goal, a central challenge is being able to quantitatively and longitudinally track functional...
5.
Lin E, Silvian L, Marcotte D, Banos C, Jow F, Chan T, et al.
Sci Rep
. 2018 Sep;
8(1):13438.
PMID: 30194389
Protein interacting with C kinase (PICK1) is a scaffolding protein that is present in dendritic spines and interacts with a wide array of proteins through its PDZ domain. The best...
6.
Beshore D, Di Marco C, Chang R, Greshock T, Ma L, Wittmann M, et al.
ACS Med Chem Lett
. 2018 Jul;
9(7):652-656.
PMID: 30034595
Identification of ligands that selectively activate the M muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization...
7.
Preclinical to Human Translational Pharmacology of the Novel M Positive Allosteric Modulator MK-7622
Uslaner J, Kuduk S, Wittmann M, Lange H, Fox S, Min C, et al.
J Pharmacol Exp Ther
. 2018 Mar;
365(3):556-566.
PMID: 29563325
The current standard of care for treating Alzheimer's disease is acetylcholinesterase inhibitors, which nonselectively increase cholinergic signaling by indirectly enhancing activity of nicotinic and muscarinic receptors. These drugs improve cognitive...
8.
Nobuhara C, DeVos S, Commins C, Wegmann S, Moore B, Roe A, et al.
Am J Pathol
. 2017 Apr;
187(6):1399-1412.
PMID: 28408124
The clinical progression of Alzheimer disease (AD) is associated with the accumulation of tau neurofibrillary tangles, which may spread throughout the cortex by interneuronal tau transfer. If so, targeting extracellular...
9.
Holtzman D, Carrillo M, Hendrix J, Bain L, Catafau A, Gault L, et al.
Alzheimers Dement
. 2016 May;
12(10):1033-1039.
PMID: 27154059
Alzheimer's Association Research Roundtable Fall 2015-Tau: From research to clinical development. Tau pathology is recognized as the key driver of disease progression in Alzheimer's and other neurodegenerative diseases. Although this...
10.
Vardigan J, Cannon C, Puri V, Dancho M, Koser A, Wittmann M, et al.
Psychopharmacology (Berl)
. 2014 Dec;
232(11):1859-66.
PMID: 25491927
Rationale: The standards of care for Alzheimer's disease, acetylcholinesterase inhibitors such as donepezil (Aricept®), are dose-limited due to adverse side-effects. These adverse events lead to significant patient non-compliance, constraining the...